MedTrace Logo

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

NCT02863419 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 711

Last updated 2022-07-20

Study results available
· View outcomes & findings →

Summary

This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.

Conditions

Interventions

DRUG

semaglutide

Oral semaglutide once-daily.

DRUG

liraglutide

Subcutaneous (s.c.) injection once-daily.

DRUG

placebo

Placebo once-daily.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-10
Primary Completion
2017-08-19
Completion
2018-03-30
FDA Drug
Yes

Countries

  • United States
  • Croatia
  • Czechia
  • Germany
  • Hungary
  • Japan
  • Latvia
  • Poland
  • Puerto Rico
  • Slovakia
  • South Africa
  • Ukraine
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02863419 on ClinicalTrials.gov